Hengrui Medicine's "Azilsartan Tablets" will be approved soon

On May 31, the Insight intelligence monitoring system showed that the listing application of Hengrui's 3 generic drug "Azilsartan Tablets" was "under review" (acceptance number: CYHS1700171, CYHS1700170), and two rounds of supplementary information were passed through the review process And the clinical trial on-site verification is expected to be approved soon.

Azilsartan (azilsartan) is a new generation of selective AT1 subtype angiotensin II receptor antagonists (ARBs) antihypertensive drug developed by Takeda Pharmaceutical, which can antagonize angiotensin by binding to angiotensin II receptors.

Azilsartan was first developed by Japan's Takeda Pharmaceutical Company and was approved in Japan in January 2012, and was listed under the name "Azilva".

It is understood that the total sales of angiotensin inhibitor drugs in China in 2017 was 9.

Imitated by more than 60 domestic pharmaceutical companies

According to the Insight database, as of May 2021, there are 59 domestic companies under research for Azilsartan tablets, and 4 companies including Hengrui, Yangzijiang Pharmaceutical and Zhaoke Pharmaceutical are in the process of listing applications.

From: Insight database (http://db.

Among the first tier of listing applications, Hengrui Pharmaceuticals has made the fastest progress, followed by Zhaoke Pharmaceuticals and Baiao Pharmaceuticals.

Hengrui began to apply for clinical approval to NMPA in 2012.

According to Hengrui's 2018 annual report, as of the end of 2018, Hengrui's Azilsartan tablet research and development project has invested about 9.